

Felix Y Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2856517/publications.pdf>

Version: 2024-02-01

289
papers

27,684
citations

11235

73
h-index

7627

156
g-index

294
all docs

294
docs citations

294
times ranked

32961
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	2.0	15
2	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
3	Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. <i>Cancer Research</i> , 2022, 82, 155-168.	0.4	29
4	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. <i>Molecular Oncology</i> , 2022, 16, 2451-2469.	2.1	8
5	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. <i>Nature Communications</i> , 2022, 13, 141.	5.8	76
6	Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC δ 1. <i>Oncogene</i> , 2022, , .	2.6	5
7	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	2.0	17
8	Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2022, 81, 437-439.	0.9	0
9	Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. <i>Cell Chemical Biology</i> , 2022, 29, 490-501.e4.	2.5	6
10	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	5.1	68
11	Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 520-522.	0.8	0
12	Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 277-277.	0.8	0
13	Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.. <i>Journal of Clinical Oncology</i> , 2022, 40, 265-265.	0.8	0
14	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	2.6	32
15	Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.. <i>Journal of Clinical Oncology</i> , 2022, 40, 109-109.	0.8	0
16	An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.. <i>Journal of Clinical Oncology</i> , 2022, 40, 223-223.	0.8	9
17	Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 222-222.	0.8	1
18	Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.. <i>Journal of Clinical Oncology</i> , 2022, 40, 269-269.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 167-167.	0.8	0
20	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 278-289.	0.4	4
21	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	0.9	19
22	Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer. Clinical Epigenetics, 2022, 14, 60.	1.8	8
23	The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet, The, 2022, 399, 1886-1901.	6.3	89
24	The Time to Evaluate the Impact of PET PSMA on Management of Prostate Cancer Is Now. International Journal of Radiation Oncology Biology Physics, 2022, 113, 254-255.	0.4	0
25	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
26	Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials.. Journal of Clinical Oncology, 2022, 40, 5039-5039.	0.8	0
27	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. Journal of Clinical Oncology, 2022, 40, 3172-3179.	0.8	14
28	Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. Science Translational Medicine, 2022, 14, .	5.8	12
29	Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials.. Journal of Clinical Oncology, 2022, 40, 108-108.	0.8	1
30	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.	3.2	10
31	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5011-5011.	0.8	2
32	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discovery, 2022, 12, 2074-2097.	7.7	22
33	Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance.. Journal of Clinical Oncology, 2022, 40, 5058-5058.	0.8	0
34	Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clinical Cancer Informatics, 2022, , .	1.0	0
35	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.4	77
36	Doseâ€“response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213.	0.3	24

#	ARTICLE	IF	CITATIONS
37	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
38	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
39	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. <i>Nature Communications</i> , 2021, 12, 401.	5.8	60
40	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	0.9	61
41	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. <i>Scientific Reports</i> , 2021, 11, 5040.	1.6	40
42	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	2.0	15
43	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
44	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1781.	5.8	32
45	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. <i>PLoS ONE</i> , 2021, 16, e0249123.	1.1	4
46	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 710-725.	1.5	6
47	Long noncoding RNAs in cancer metastasis. <i>Nature Reviews Cancer</i> , 2021, 21, 446-460.	12.8	342
48	Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.. <i>Journal of Clinical Oncology</i> , 2021, 39, 512-512.	0.8	3
49	Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021, 27, 5123-5130.	3.2	65
50	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
51	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
52	A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4463-4471.	3.3	9
53	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	3.2	33
54	The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. <i>Molecular Cancer Research</i> , 2021, 19, 1778-1791.	1.5	20

#	ARTICLE	IF	CITATIONS
55	Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 634-635.	0.4	0
56	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. European Urology, 2021, 80, 71-81.	0.9	35
57	An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nature Communications, 2021, 12, 4601.	5.8	18
58	Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology, 2021, 155, 199-209.	0.5	0
59	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. Npj Genomic Medicine, 2021, 6, 76.	1.7	10
60	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	4.6	72
61	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
62	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	0.5	11
63	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	3.4	21
64	Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Physics in Medicine and Biology, 2021, 66, 035016.	1.6	17
65	Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. BMJ Evidence-Based Medicine, 2021, 26, bmjebm-2020-111592.	1.7	0
66	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	5.8	51
67	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	2.8	16
68	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	0.9	65
69	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 136-143.	2.0	36
70	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology, 2020, 77, 201-208.	0.9	37
71	SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. Scientific Reports, 2020, 10, 15890.	1.6	3
72	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	1.5	2

#	ARTICLE	IF	CITATIONS
73	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
74	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , 2020, 1, 1082-1096.	5.7	49
75	The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115712.	1.4	16
76	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
77	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
78	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020, 145, 197-203.	0.5	1
79	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	0.9	9
80	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	3.2	10
81	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , 2020, 22, 34-44.	0.2	7
82	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020, 11, 5549.	5.8	76
83	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
84	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
85	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
86	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
87	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 936-940.	0.4	3
88	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	0.8	170
89	Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells. <i>Neoplasia</i> , 2020, 22, 192-202.	2.3	15
90	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58

#	ARTICLE	IF	CITATIONS
91	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 171-182.	3.2	14
92	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	1.0	10
93	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16.	0.8	4
94	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	1.5	24
95	Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 351-370.	7.7	162
96	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
97	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	2.6	51
98	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1965-1976.	3.2	55
99	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	3.2	273
100	Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. <i>Nature Communications</i> , 2019, 10, 3107.	5.8	28
101	Reply to J.B. Aragon-Ching. <i>Journal of Clinical Oncology</i> , 2019, 37, 2297-2298.	0.8	0
102	Author Reply. <i>Urology</i> , 2019, 129, 163-164.	0.5	1
103	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 5623-5637.	3.2	23
104	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
105	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 685-690.	2.6	21
106	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.4	10
107	Cleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. <i>Radiotherapy and Oncology</i> , 2019, 141, 137-143.	0.3	8
108	What Is Oligometastatic Prostate Cancer?. <i>European Urology Focus</i> , 2019, 5, 159-161.	1.6	24

#	ARTICLE	IF	CITATIONS
109	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	2.8	17
110	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 59-68.	0.9	112
111	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, 278.	5.8	143
112	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
113	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
114	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.4	247
115	Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 1652-1664.	1.5	10
116	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	0.9	28
117	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	0.8	8
118	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. <i>Theranostics</i> , 2019, 9, 2812-2826.	4.6	20
119	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019, 25, 4290-4299.	3.2	38
120	Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. <i>Urology</i> , 2019, 129, 165-171.	0.5	41
121	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.	1.5	51
122	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
123	Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. <i>European Urology</i> , 2019, 76, 338-339.	0.9	1
124	AUTHOR REPLY. <i>Urology</i> , 2019, 125, 161-162.	0.5	0
125	Reply to A. Dalla Volta et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-352.	0.8	0
126	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	0.9	104

#	ARTICLE	IF	CITATIONS
127	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 2580-2592.	0.4	85
128	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	13.5	317
129	The long noncoding <i>RNA</i> <i>HORAS</i> mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. <i>Molecular Oncology</i> , 2019, 13, 1121-1136.	2.1	28
130	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	2.0	66
131	Linking the Y Chromosome to Prostate Cancer: TTY15 Takes Center Stage. <i>European Urology</i> , 2019, 76, 327-328.	0.9	2
132	Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 168-170.	1.6	1
133	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
134	A Tumor-Agnostic NTRK (TRK) Inhibitor. <i>Cell</i> , 2019, 177, 8.	13.5	41
135	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019, 2, 405-412.	2.6	14
136	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plans in Patients With Prostate Cancer. <i>Urology</i> , 2019, 125, 154-162.	0.5	20
137	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	3.2	52
138	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	0.9	18
139	Long non-coding RNAs in prostate cancer: Biological and clinical implications. <i>Molecular and Cellular Endocrinology</i> , 2019, 480, 142-152.	1.6	12
140	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
141	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	1.6	40
142	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. <i>Journal of Urology</i> , 2019, 201, 284-291.	0.2	18
143	RNA Biomarkers: Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection (<i>Adv. Healthcare Mater.</i> 3/2018). <i>Advanced Healthcare Materials</i> , 2018, 7, 1870013.	3.9	3
144	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72

#	ARTICLE	IF	CITATIONS
145	MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions. <i>Bioinformatics</i> , 2018, 34, 3101-3110.	1.8	48
146	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018, 16, 643-654.	1.5	33
147	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	0.9	29
148	Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. <i>Cell Reports</i> , 2018, 22, 3672-3683.	2.9	95
149	Live to SABR Another Day?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1097.	0.4	0
150	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
151	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 274-284.	0.4	50
152	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
153	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	1.3	24
154	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	0.9	55
155	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	1.1	27
156	Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700701.	3.9	38
157	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	2.0	21
158	Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>Eur Urol</i> 2018;73:156-65. <i>European Urology</i> , 2018, 73, e64-e65.	0.9	2
159	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	0.8	477
160	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	0.8	162
161	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169
162	Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1317-1322.	0.8	60

#	ARTICLE	IF	CITATIONS
163	Genomic biomarkers in prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 459-471.	0.6	46
164	Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2018, 1, 323-324.	2.6	1
165	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
166	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2018, 19, e683-e695.	5.1	74
167	PARP1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	52
168	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
169	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
170	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	0.9	55
171	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , 2018, 24, 3500-3509.	3.2	3
172	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018, 174, 564-575.e18.	13.5	264
173	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
174	Prostate cancer in the era of "Omics" medicine: recognizing the importance of DNA damage repair pathways. <i>Annals of Translational Medicine</i> , 2018, 6, 161-161.	0.7	7
175	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018, 173, 1770-1782.e14.	13.5	400
176	EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. <i>Cancer Research</i> , 2018, 78, 4760-4773.	0.4	55
177	Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.. <i>Journal of Clinical Oncology</i> , 2018, 36, 197-197.	0.8	3
178	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 726-732.	0.4	11
179	Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 417-428.	13.9	506
180	Anatomical patterns of recurrence following biochemical relapse after postprostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	1.3	10

#	ARTICLE	IF	CITATIONS
181	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
182	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	7.7	223
183	External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. <i>Brachytherapy</i> , 2017, 16, 782-789.	0.2	7
184	Impact of ⁶⁸ Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1956-1961.	2.8	111
185	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	2.9	99
186	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	1.0	15
187	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. <i>European Urology</i> , 2017, 72, 845-852.	0.9	79
188	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	0.8	6
189	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5207-E5215.	3.3	266
190	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.4	9
191	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	2.0	14
192	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.4	94
193	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017, 77, 982-995.	0.4	67
194	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. <i>Cancer Research</i> , 2017, 77, 960-970.	0.4	78
195	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5479-5490.	0.4	71
196	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
197	Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. <i>Prostate International</i> , 2017, 5, 89-94.	1.2	3
198	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , 2017, 77, 4745-4754.	0.4	56

#	ARTICLE	IF	CITATIONS
199	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017, 171, 1559-1572.e20.	13.5	200
200	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 695-699.	1.0	0
201	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
202	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.2	76
203	Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2017, 27, 11-20.	1.0	8
204	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw200.	3.0	150
205	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	0.8	45
206	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	0.8	176
207	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 341-358.	3.9	83
208	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 1, 1-6.	0.4	23
209	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016, 118, 279-285.	1.3	14
210	Independent surgical validation of the new prostate cancer grade-grouping system. <i>BJU International</i> , 2016, 118, 763-769.	1.3	48
211	Racial/Ethnic Disparities in Genomic Sequencing. <i>JAMA Oncology</i> , 2016, 2, 1070.	3.4	250
212	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. <i>Head and Neck</i> , 2016, 38, E1086-96.	0.9	41
213	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 489-499.	2.3	55
214	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.	3.2	99
215	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	0.8	18
216	Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 354-361.	0.4	63

#	ARTICLE	IF	CITATIONS
217	MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. <i>Neoplasia</i> , 2016, 18, 213-222.	2.3	51
218	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. <i>Urology Case Reports</i> , 2016, 9, 51-54.	0.1	0
219	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1046-1053.	0.4	47
220	Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>Eur Urol</i> 2016;69:50â€“7. <i>European Urology</i> , 2016, 70, e159.	0.9	0
221	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.2	13
222	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3648-3654.	0.8	296
223	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. <i>Nature Genetics</i> , 2016, 48, 1142-1150.	9.4	196
224	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	2.0	27
225	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182
226	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	5.8	196
227	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	2.3	10
228	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
229	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016, 122, 1505-1512.	2.0	27
230	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	2.3	25
231	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	3.4	46
232	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 324-331.	1.5	137
233	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.	3.2	42
234	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.2	89

#	ARTICLE	IF	CITATIONS
235	microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. <i>Molecular Biology Reports</i> , 2016, 43, 229-240.	1.0	12
236	Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 473-475.	3.3	7
237	Overexpression of the Long Non-coding RNA SCHLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , 2016, 70, 549-552.	0.9	121
238	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	1.3	45
239	Long noncoding RNAs in prostate cancer: overview and clinical implications. <i>Asian Journal of Andrology</i> , 2016, 18, 568.	0.8	41
240	Development and Validation of a Novel Platform-Independent Metastasis Signature in Human Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0126631.	1.1	12
241	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
242	Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 944-951.	0.8	196
243	Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3667-3677.	3.2	130
244	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.4	94
245	Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. <i>Brachytherapy</i> , 2015, 14, 502-510.	0.2	23
246	Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. <i>Neoplasia</i> , 2015, 17, 490-496.	2.3	8
247	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 297-311.	1.4	43
248	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , 2015, 47, 199-208.	9.4	2,410
249	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	0.9	125
250	Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. <i>Urology</i> , 2015, 86, 35-40.	0.5	27
251	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , 2015, 28, 97-113.	7.7	148
252	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. <i>Neoplasia</i> , 2015, 17, 385-399.	2.3	212

#	ARTICLE	IF	CITATIONS
253	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Molecular Cell</i> , 2015, 58, 925-934.	4.5	114
254	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	0.5	12
255	Long-Term Quality of Life After Swallowing and Salivary-Sparing Chemo-Intensity Modulated Radiation Therapy in Survivors of Human Papillomavirus-Related Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 925-933.	0.4	83
256	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015, 21, 344-352.	15.2	165
257	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	13.9	1,796
258	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	1.2	10
259	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 179-184.	0.3	61
260	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 828-835.	0.4	40
261	The lncRNAs <i>PCGEM1</i> and <i>PRNCR1</i> are not implicated in castration resistant prostate cancer. <i>Oncotarget</i> , 2014, 5, 1434-1438.	0.8	106
262	A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA <i>SChLAP1</i> Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. <i>Neoplasia</i> , 2014, 16, 1121-1127.	2.3	81
263	MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?. <i>Radiology and Oncology</i> , 2014, 48, 323-330.	0.6	9
264	The Long Non-Coding RNA <i>PCAT-1</i> Promotes Prostate Cancer Cell Proliferation through cMyc. <i>Neoplasia</i> , 2014, 16, 900-908.	2.3	216
265	A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer. <i>Translational Oncology</i> , 2014, 7, 644-649.	1.7	63
266	Editorial Comment. <i>Urology</i> , 2014, 84, 1432-1433.	0.5	0
267	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of <i>SChLAP1</i> . <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	5.1	226
268	Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. <i>Radiation Oncology</i> , 2014, 9, 245.	1.2	2
269	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4442-4448.	3.2	54
270	A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. <i>Clinical Cancer Research</i> , 2014, 20, 6379-6388.	3.2	12

#	ARTICLE	IF	CITATIONS
271	A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer ^{1,2} . <i>Translational Oncology</i> , 2014, 7, 429-438.	1.7	33
272	A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. <i>Practical Radiation Oncology</i> , 2014, 4, 422-429.	1.1	7
273	The central role of EED in the orchestration of polycomb group complexes. <i>Nature Communications</i> , 2014, 5, 3127.	5.8	130
274	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. <i>Urology</i> , 2014, 84, 373-379.	0.5	14
275	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014, 510, 278-282.	13.7	811
276	The lncRNA <i>PCAT29</i> Inhibits Oncogenic Phenotypes in Prostate Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 1081-1087.	1.5	119
277	Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 81-94.	1.1	34
278	Patient-Reported Voice and Speech Outcomes After Whole-Neck Intensity Modulated Radiation Therapy and Chemotherapy for Oropharyngeal Cancer: Prospective Longitudinal Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 973-980.	0.4	37
279	Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, 99-107.	1.1	9
280	The long noncoding RNA <i>SCHLAP1</i> promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013, 45, 1392-1398.	9.4	601
281	Larger Maximum Tumor Diameter at Radical Prostatectomy Is Associated With Increased Biochemical Failure, Metastasis, and Death From Prostate Cancer After Salvage Radiation for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 275-281.	0.4	10
282	Retrospective Evaluation Reveals That Long-term Androgen Deprivation Therapy Improves Cause-Specific and Overall Survival in the Setting of Dose-Escalated Radiation for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 64-71.	0.4	16
283	The addition of low-dose-rate brachytherapy and androgen deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. <i>Cancer</i> , 2013, 119, 681-690.	2.0	44
284	A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult. <i>Cancer Discovery</i> , 2013, 3, 1254-1271.	7.7	294
285	Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. <i>Cancer</i> , 2013, 119, 3287-3294.	2.0	51
286	Gleason Pattern 5 Is the Greatest Risk Factor for Clinical Failure and Death From Prostate Cancer After Dose-Escalated Radiation Therapy and Hormonal Ablation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e351-e360.	0.4	68
287	Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. <i>Journal of Clinical Oncology</i> , 2010, 28, 2732-2738.	0.8	305
288	Radiation therapy improves survival in patients with pancreatic adenocarcinoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 434-435.	4.3	0

#	ARTICLE	IF	CITATIONS
289	Intensity-Modulated Radiotherapy of Head and Neck Cancer Aiming to Reduce Dysphagia: Early Dose-Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1289-1298.	0.4	434